Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2019 · 10-Q
Revenue$51.69K$51.69K−41.5% vs Q3 2018 Net Income-$4.14M-$4.14MN/M vs Q3 2018 EPS Diluted-$0.71-$0.71N/M vs Q3 2018 Operating Income-$4,207,476N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,249,825N/M Margins · derivedOperating margin-8140.3%−3777.2 pt vs Q3 2018
Net margin-8012.7%−3746.6 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 7, 2019 · 38 d after period end